Mirum Pharmaceuticals

Scroll
Investment area
Novo Ventures
Region
Western USA
Date of investment
November 2018
Website
https://mirumpharma.com/

The pipeline of Mirum Pharmaceuticals consists of two clinical-stage product candidates with mechanisms of action that have potential utility across a wide range of rare liver diseases. We are advancing our lead candidate, maralixibat for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) — conditions with a profound and devastating impact on quality of life for young patients and their families.